Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2003-12-15
2008-12-02
Kam, Chih-Min (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S334000, C530S345000, C530S317000, C514S002600, C514S012200
Reexamination Certificate
active
07459522
ABSTRACT:
Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain R1and a second peptide chain R2, wherein R1and R2may be the same or different, and are linked through a linking moiety. R1is approximately 10 to 40 amino acid residues in length and comprises the sequence X3X4X5GPX6TX7X8X9(SEQ ID NO: 1) wherein X3is C or Hoc, X4is R, H, L or W, X5is M, F, I or nor-leucine (J), X6is any one of the 20 genetically coded L-amino acids or J, X7is W, 1-naphthylalanine (B) or 2-naphthylalanine (U), X8is D, E, I, L or V, and X9is C or Hoc. Similarly, R2comprises the sequence X′3X′4X′5GPX′6TX′7X′8X′9(SEQ IN NO: 2) wherein X′3is C or Hoc, X′4is R, H, L or W, X′5is M, F, I or J, X′6is any one of the 20 genetically coded L-amino acids or J, X′7is W, B or U, X8′ is D, E, I, L or V, and X′9is C or Hoc. Methods for synthesizing the compounds are provided as well, as are pharmaceutical compositions and methods of use.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4612132 (1986-09-01), Wollenberg
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki
patent: 4677195 (1987-06-01), Hewick et al.
patent: 4703008 (1987-10-01), Lin et al.
patent: 4791192 (1988-12-01), Nakagawa
patent: 5061786 (1991-10-01), Burnier
patent: 5106954 (1992-04-01), Fibi et al.
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5278065 (1994-01-01), D'Andrea
patent: 5322837 (1994-06-01), Hewick et al.
patent: 5369014 (1994-11-01), Brugnara et al.
patent: 5399551 (1995-03-01), Ise et al.
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5482924 (1996-01-01), Royet et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5770358 (1998-06-01), Dower et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 6703480 (2004-03-01), Balu
patent: 712713 (1996-12-01), None
patent: 2021528 (1991-01-01), None
patent: 0148605 (1985-07-01), None
patent: 0427189 (1991-05-01), None
patent: 0428267 (1991-05-01), None
patent: WO 90/08822 (1990-08-01), None
patent: WO 90/15070 (1990-12-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 93/23550 (1993-11-01), None
patent: WO 93/25221 (1993-12-01), None
patent: WO 94/02611 (1994-02-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/25746 (1995-09-01), None
patent: WO 96/40749 (1996-12-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 01/38342 (2001-05-01), None
Amagnostou, et al., “Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells”, Proc. Natl. Acad. Sci. USA 87: 5978-5982, (1990).
Ando, et al., “Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells”, Proc. Natl. Acad. Sci. USA 90: 9571-9575, (1993).
Barker, et al., “Cyclic RGD Peptide Analogues as antiplatelet Antithrombotics”, J. Med. Chem. 35: 2040-2048, (1992).
Bodonsky, et al., “Active Esters and Resins in Peptide Synthesis”, Chem. Ind. 38:1597, (1996).
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science 247:1306-1310, (1990).
Branch, et al., “Identification of an Erythoropoietin Sensitive Cell Line”, Blood 69:1782-1785, (1987).
Caras, et al., “Signal Peptide for Protein Secretion Directing Glycophospholip Membran Anchor Attachment”, Science 243:1196-1198, (1989).
Claus-Walker, et al., “Spinal Cord Injury and Serum Erythropoietin”, Arch. Phys. Med. Rehabil. 65:370-374, (1984).
Cotes, et al., “Changes in serum immunoreactive erythropoietin during the menstrual cycle and normal pregnancy”, Brit. J. Obstetrics and Gynaecology, 90:305-311, (1983).
Cwirla, et al., “Peptides on phage: A vast library of peptides for identifying ligands”, Proc. Natl. Acad. Sci. USA 87:6378-6382, (1990).
Dainak, et al., “Mechanisms of Abnormal Erythropoiesis in malignancy”, Cancer 5, 1101-1106, (1983).
Dexter, et al., “Growth of Factor-Dependent Hematopoetic Precursor Cell Lines”, J. Exp. Med. 152:1036-1047, (1980).
Dower, et al., The search for Molecular Diversity (II): Recombinant and synthetic randomized Peptide libraries: Ann. Rep. Med. Chem. 26:271-280, (1991).
Dunn, et al., “Serum Erythropoietin Titers During Prolonged Bedrest: Relevance to the “Anaemia” of space flight”, Eur. J. Appl. Physiol. 52: 178-182, (1984).
Dusanter-Fourt, et al., “Erythropoitin induces the tyrosine Phosphorylation of its own receptor in human Erythropoietin-responsive cells”, J. Biol. Chem. 287:10670-10678, (1992).
Eschbach, et al., “Correction of the Anemia of End-Stage Renal Disease with Recombinant human erythropoietin”, N. Eng. J. Med. 316: 73-78, (1987).
Fodor, et al., “Light-Directed, Spatially addressable parallel chemical synthesis”, Science, 251:767-773, (1991).
Graber, et al., “Erythropoietin and the control of red cell production”, Ann. Rev. Med., 29:51-66, (1978).
Greenberger, et al., “Demonstration of permanent factor-dependent multipotential erythroid
eutrophil/basophil) hematopoietic progenitor cell lines”, Proc. Natl. Acad. Sci. US 80:2931-2935, (1983).
Haga, et al., “Plasma Erythropoietin Concentrations during the early Anemia of Prematurity”, Acta Paediatr. Scand., 72: 827-831, (1983).
Kaiho, et al., “Sensitive Assay Systems for Detection of Hemoglobin with 2,7-Diaminoflourence: Histochemistry and Colorimetry for Erythrodifferentiation”, Anal. Biochem. 149:177-120, (1985).
Kitamura, et al., “Identification and Analysis of Human Erythopoietin Receptors on a Factor-Dependent Cell Line, TF-1”, Blood 73(2):375-280, (1989).
Krantz, et al., “Specific Binding of Erythropoietin to spleen cells infected with the anemia Strain of friend virus”, Proc. Natl. Acad. Sci. USA 81:7574-7578, (1984).
Krystal, Gerald “A Simple microassay for Erythropoietin based on H-thymidine Incorporation into Spleen calls from Phenylhydrazine Treated Mice”, Exp. Hematol., 11(7):649-660, (1983).
Konishi, et al., “Trophic effect of Erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro in vivo”, Brain Res., 609: 29-35, (1993).
Landschulz, et al., “Erythropoietin receptors on murine erythroid colony-forming units: Natural History”, Blood 73: 1476-1478, (1989).
Leonard, et al., “Dynamics of GATA Transcript factor expression during erythroid differentiation”, Blood, 82: 1071-1079, (1993).
Lin, et al., “Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form”, Science, 249:677-679, (1990).
Lipschitz, et al., “Effect of Age Hematopoiesis in Man”, Blood, 63:502-509, (1983).
Livnah, et al., “Functional Mimicry of a Protein Hormone by a Peptide Agonist: The Structure of the EPOR complex to 2.8Å”, Science 273:464-471, (1996).
Mayeux, et al., “Murine erythroleukaemia cells (Friend cells) possess high-affinity binding sites for eryropoietin”, FEBS Lett., 211: 229-233, (1987).
Merrifield “Solid Phase Peptide Synthesis. The Synthesis of a Teterapeptide”, J. Am. Chem. Soc., 85:2149, (1963).
Miller, et al., “Plasma Levels of Immunoreactive Erythropoietin after acute blood loss in man”, Brit. J. Haematol., 52: 545-590, (1982).
Morgan and Gainor, et al., “Approaches to the discovery of non-peptide lignads for peptide receptors and peptidase”, Ann. Rep. Med. Chem., 24:243-252, (1989).
Mosmann “Rapid Colorimetric Assay for cellular g
Affymax, Inc.
Goodwin & Procter LLP
Kam Chih-Min
LandOfFree
Peptide dimers as agonists of the erythropoietin (EPO)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide dimers as agonists of the erythropoietin (EPO)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide dimers as agonists of the erythropoietin (EPO)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033888